NCT07522099Phase 2Recruiting

Chinese Adults With Kidney Disease

Study sponsor: ADARx Pharmaceuticals, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-07-10Estimated

Enrollment · participants30Estimated

Source updated2026-09-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-14 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Not yet recruiting

+ Updated value

Recruiting

Check registry source

Study details

Conditions studied

Immunoglobulin A Nephropathy (IgAN); Complement 3 Glomerulopathy (C3G); IC-MPGN

Treatments or interventions studied

ADX-038Drug
TelitaciceptDrug

Primary outcomes · main study measures

measure: Evaluate the safety and tolerability of ADX-038 as a monotherapy and in combination with telitacicept; description: Evaluate the proportion of patients with treatment emergent adverse events (TEAEs) with ADX-038 and telitacicept versus those on ADX-038 alone.; timeFrame: Part A - 24 Months and Part B - 15 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history